Avis de rétractation. Ce document annonce le retrait d'un article publié ; il ne présente pas de résultats de recherche.
Accès ouvert · CC BY

Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

Avis de rétractation 2021 Sciences de la santé Anglais

Résumé

After concerns were brought to the Editors' attention after publication, the raw data underlying the study were requested. The authors provided several versions of their dataset. Post-publication peer review confirmed that none of these versions fully recapitulates the results presented in the cohort background comparisons, casting doubt on the reliability of the data. Additional concerns were raised about the randomisation procedure, as the equal distribution of male and female patients is unlikely unless sex is a parameter considered during randomisation. However, based on the clarification provided by the authors, sex was not considered during this process. The Editors therefore no longer have confidence in the results and conclusions presented.

Citer ce document

Dabbous, H., El‐Sayed, M. H., Assal, G. E., Elghazaly, H., Ebeid, F. S. E., Sherief, A. F., Fawzy, E., Hassany, S. M., Riad, A. R., & Tageldin, M. A. (2021). Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Scientific Reports. https://doi.org/10.1038/s41598-021-98683-5

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 05/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 16

Téléchargements (hors robots) : 0

Méthode de comptage